Market capitalization | CHF3.57b |
Enterprise Value | CHF3.54b |
P/E (TTM) P/E ratio | 35.20 |
EV/FCF (TTM) EV/FCF | 31.40 |
EV/Sales (TTM) EV/Sales | 3.54 |
P/S ratio (TTM) P/S ratio | 3.57 |
P/B ratio (TTM) P/B ratio | 2.54 |
Dividend yield | 1.08% |
Last dividend (FY23) | CHF3.00 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Tecan Group Ltd. forecast:
8 Analysts have issued a Tecan Group Ltd. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,000 1,000 |
9%
9%
|
|
Gross Profit | 347 347 |
15%
15%
|
|
EBITDA | 162 162 |
16%
16%
|
EBIT (Operating Income) EBIT | 91 91 |
29%
29%
|
Net Profit | 101 101 |
7%
7%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tecan Group AG operates as a holding company. The firm engages in the development, production and distribution of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. It operates through the following segments: Life Sciences Business and Partnering Business. The Life Sciences Business segment supplies end users with automated workflow solutions, which includes laboratory instruments, software packages, application know-how, services, consumables and spare parts. The Partnering Business segment develops and manufactures original equipment manufacturer instruments and components. The company was founded by Heinz Abplanalp, Heini Maurer, Heini Moeckli and Gallus Blatter on March 18, 1980 and is headquartered in Mannedorf, Switzerland.
Head office | Switzerland |
CEO | Achim Leoprechting |
Employees | 3,591 |
Founded | 1980 |
Website | www.tecan.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.